Invention Grant
- Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy
-
Application No.: US15528067Application Date: 2015-11-18
-
Publication No.: US10760130B2Publication Date: 2020-09-01
- Inventor: Brian A. Elenbaas , Antonio Gualberto , Charles Praray Hart
- Applicant: MOLECULAR TEMPLATES, INC.
- Applicant Address: US TX Austin
- Assignee: MOLECULAR TEMPLATES, INC.
- Current Assignee: MOLECULAR TEMPLATES, INC.
- Current Assignee Address: US TX Austin
- Agency: Foley & Lardner LLP
- International Application: PCT/US2015/061248 WO 20151118
- International Announcement: WO2016/081547 WO 20160526
- Main IPC: C12Q1/6883
- IPC: C12Q1/6883 ; A61K31/675 ; C07F9/655 ; C07F9/6553 ; C07F9/6506 ; G01N33/573 ; C12Q1/6886 ; G01N33/574 ; A61K45/06 ; A61K31/7068 ; G01N33/50 ; A61K9/00
Abstract:
Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
Public/Granted literature
- US20180334716A1 PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY Public/Granted day:2018-11-22
Information query
